Abstract: Polymorphic forms of deoxycytidine and methods for preparing the same are provided herein. Also provided are compositions comprising polymorphic forms of deoxycytidine and at least one residual solvent, as well as methods of treating mitochondrial diseases using said compositions.

Abstract: Provided are compositions comprising a first heteroaryl compound and a second heteroaryl compound dissolved in an aqueous liquid. Also provided are methods of treating a patient that include orally administering such an aqueous liquid to a patient, for example, wherein the patient has been diagnosed with a mitochondrial depletion syndrome. Kits are provided that include the first heteroaryl compound, the second heteroaryl compound, and optionally instructions for dissolving the first heteroaryl compound and the second heteroaryl compound in an aqueous liquid and administering the solution to a patient.

Abstract: Methods of stabilizing transthyretin (TTR) tetramers in the biological fluids of human patients comprising administering a catechol-O-methyltransferase (COMT) inhibitor are provided. Also provided are methods of treating human patients with TTR-associated amyloidosis comprising administering a COMT inhibitor the crosses the blood brain barrier and stabilizes TTR in the cerebrospinal fluid (CSF) of a patient.

Abstract: Polymorphic forms of deoxycytidine and methods for preparing the same are provided herein. Also provided are compositions comprising polymorphic forms of deoxycytidine and at least one residual solvent, as well as methods of treating mitochondrial diseases using said compositions.

Abstract: The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to multi-unit complexes of tRNA synthetase fragments and uses thereof; diverse multi-unit complexes including a tRNA synthetase fragment; compositions and methods for modulating angiogenesis; polynucleotides encoding tRNA synthetase fragments and uses thereof; antibodies and epitopes specific to tRNA synthetase fragments; variants of tRNA synthetase fragments and uses thereof; methods for treating angiogenesis; methods for screening for anti-angiogenic agents; methods of modulating angiogenesis; kits for modulating angiogenesis; and business methods for modulating angiogenesis. Preferably the tRNA synthetase fragments are tryptophanyl tRNA synthetase fragments, and more preferably human tryptophanyl tRNA synthetase fragments.

Abstract: The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to multi-unit complexes of tRNA synthetase fragments and uses thereof; diverse multi-unit complexes including a tRNA synthetase fragment; compositions and methods for modulating angiogenesis; polynucleotides encoding tRNA synthetase fragments and uses thereof; antibodies and epitopes specific to tRNA synthetase fragments; variants of tRNA synthetase fragments and uses thereof; methods for treating angiogenesis; methods for screening for anti-angiogenic agents; methods of modulating angiogenesis; kits for modulating angiogenesis; and business methods for modulating angiogenesis. Preferably the tRNA synthetase fragments are tryptophanyl tRNA synthetase fragments, and more preferably human tryptophanyl tRNA synthetase fragments.

Abstract: The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to multi-unit complexes of tRNA synthetase fragments and uses thereof; diverse multi-unit complexes including a tRNA synthetase fragment; compositions and methods for modulating angiogenesis; polynucleotides encoding tRNA synthetase fragments and uses thereof; antibodies and epitopes specific to tRNA synthetase fragments; variants of tRNA synthetase fragments and uses thereof; methods for treating angiogenesis; methods for screening for anti-angiogenic agents; methods of modulating angiogenesis; kits for modulating angiogenesis; and business methods for modulating angiogenesis. Preferably the tRNA synthetase fragments are tryptophanyl tRNA synthetase fragments, and more preferably human tryptophanyl tRNA synthetase fragments.

Abstract: The present invention provides compositions of saratin and methods of use thereof. One aspect of the invention is a method of prevention or mitigation of the development of adhesions, keloids and scars. The adhesions, keloids and scars can be due to surgery, such as plastic surgery or orthopedic surgery, or can be pre-existing scars. Another aspect of the invention is a method for treatment of flexor tendon injuries.

Abstract: The present invention relates to methods for treating an angiogenesis mediated condition. In particular, the present invention relates to the use of a multi-unit complex that includes a tRNA synthetase fragment or a homolog or analog thereof to treat such conditions. In some embodiments, the multi-unit complex is a dimer or a homodimer of a tRNA synthetase fragment.

Abstract: The present invention relates to analogs of tRNA synthetase fragments and various uses thereof. In some embodiments, the tRNA synthetase fragment is a human tRNA synthetase fragment. In some embodiments, the tRNA synthetase fragment is a tryptophanyl tRNA synthetase fragment. The analogs herein can be used to modulate angiogenesis.

Abstract: The present invention relates to methods for modulating angiogenesis. In some embodiments the methods include a step of contacting a cell experiencing or susceptible to angiogenesis with a composition comprising a multi-unit complex that comprises a tRNA synthetase fragment. The multi-unit complex can include two or more monomer units. Two monomer units of a complex can be covalently or non-covalently linked. The multi-unit complexes herein may be formulated as pharmaceutical formulations to modulate angiogenesis.

Abstract: The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to polynucleotides encoding a tRNA synthetase fragment, or more two or more tRNA synthetase fragments.

Abstract: The present invention relates to methods for screening for anti-angiogenic agents. Such methods may include the steps of contacting a receptor of a tRNA synthetase fragment with a member of a library of candidate agents and selecting a candidate agent from the library that selectively binds to such receptor.

Abstract: The present invention relates to antibodies that specifically bind to an epitome of a tRNA synthetase fragment. Such epitopes are preferably N-terminus epitopes or bind to the N-terminus of a tRNA synthetase fragment. The invention also relates to epitope peptides useful in generating the above antibodies.

Abstract: The present invention relates to compositions comprising a Met-tRNA synthetase fragment and a non-Met-tRNA synthetase fragment as well as uses thereof. In some embodiments, the Met-tRNA synthetase fragment is more than 50% of the composition. In other embodiments, the non-Met-tRNA synthetase fragment is more than 50% of the composition. Such compositions may be used to modulate angiogensis.

Abstract: The present invention relates business methods comprising the steps of commercializing a tRNA synthetase fragment or a multi-unit complex comprising a tRNA synthetase fragment for modulating an angiogenesis-mediated condition. In some embodiments, the business methods herein include the step of expressing a tRNA synthetase fragment recombinantly. In some embodiments, the business methods herein include the step of optimizing a tRNA synthetase fragment to enhance its binding affinity to a receptor.

Abstract: The present invention relates to kits for modulating angiogenesis. In some embodiments, a kit of the present invention comprises a container comprising a multi-unit complex wherein at least one unit of said multi-unit complex comprises a tRNA synthetase fragment or a homolog or analog thereof. In some embodiments, a kit of the present invention further comprises a diagnostic tool.

Abstract: The present invention relates to a multi-unit complex of a tRNA synthetase fragment. The multi-unit complexes can comprise of two or more monomer units. Two monomer units can be covalently or non-covalently linked. The multi-unit complexes may further be used, for example, in pharmaceutical formulation to modulate angiogenesis.

Abstract: The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to variants of tRNA synthetase fragments, or more preferably tryptophanyl tRNA synthetase fragments, or more preferably human tryptophanyl tRNA synthetase fragments.

Abstract: The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to variants of tRNA synthetase fragments, or more preferably tryptophanyl tRNA synthetase fragments, or more preferably human tryptophanyl tRNA synthetase fragments.